Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.
The last earnings update was 375 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Anthera Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Anthera Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anthera Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Anthera Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Anthera Pharmaceuticals's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Anthera Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Anthera Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Anthera Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Anthera Pharmaceuticals's filings and announcements here.
Anthera Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Anthera Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Anthera Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Anthera Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Anthera Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Anthera Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. John Craig Thompson has been Chief Executive Officer & Director since December 06, 2016 and served as the President of Anthera Pharmaceuticals, Inc. since January 7, 2016. Mr. Thompson served as the Chief Operating Officer of Anthera Pharmaceuticals, Inc. since January 7, 2016 until December 2, 2016. He oversees both of Anthera's late stage development programs and commercial preparation efforts. He served as the Chief Operating Officer of Tetraphase Pharmaceuticals, Inc., from February 4, 2014 to December 31, 2015, where he oversaw the development and implementation of the commercial strategy as well as the business development and commercial manufacturing. Prior to Tetraphase Pharmaceuticals, he served as the Chief Commercial Officer of Trius Therapeutics, Inc. since January 10, 2011 until January 2014. He was initially responsible for developing the commercial strategy, positioning and planning for the potential launch of torezolid phosphate, an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections. Mr. Thompson has more than 24 years of pharmaceutical marketing and sales experience. He served as Vice President of Marketing at Pfizer's Specialty Care Business Unit, where he was directly responsible for the U.S. commercial strategy for products with over $1.5 billion in annual U.S. sales including the first generation oxazolidinone Zyvox(R), the anti-infectives Tygacil(R), Vfend(R) and Eraxis(R) as well as Rapammune(R) and Relistor(R). Prior to his 7 years at Pfizer, he served in positions of increasing responsibility during his 12 years at Merck where he most notably worked on the commercial planning and marketing activities for its anti-infectives Primaxin(R), Mefoxin(R) and Cancidas(R) as well as on major cardiovascular brands including Vytorin(R), Zetia(R) and Zocor(R) Mr. Thompson holds a degree in Commerce from McMaster University and an MBA from the University of Notre Dame.
John's compensation has been consistent with company performance over the past year, both up more than 20%.
John's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Anthera Pharmaceuticals management team is about average.
CEO & Director
Senior VP of Finance & Administration and Principal Accounting Officer
Senior Vice President of Global Regulatory Affairs and Compliance
Chief Liquidating Officer & Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Anthera Pharmaceuticals board of directors is about average.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.